Cerus PE Ratio 2010-2025 | CERS
Current and historical p/e ratio for Cerus (CERS) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cerus PE ratio as of August 22, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Cerus PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-08-22 | 1.27 | 0.00 | |
| 2025-06-30 | 1.41 | $-0.10 | 0.00 |
| 2025-03-31 | 1.39 | $-0.10 | 0.00 |
| 2024-12-31 | 1.54 | $-0.11 | 0.00 |
| 2024-09-30 | 1.74 | $-0.11 | 0.00 |
| 2024-06-30 | 1.76 | $-0.13 | 0.00 |
| 2024-03-31 | 1.89 | $-0.17 | 0.00 |
| 2023-12-31 | 2.16 | $-0.21 | 0.00 |
| 2023-09-30 | 1.62 | $-0.28 | 0.00 |
| 2023-06-30 | 2.46 | $-0.29 | 0.00 |
| 2023-03-31 | 2.97 | $-0.27 | 0.00 |
| 2022-12-31 | 3.65 | $-0.25 | 0.00 |
| 2022-09-30 | 3.60 | $-0.22 | 0.00 |
| 2022-06-30 | 5.29 | $-0.24 | 0.00 |
| 2022-03-31 | 5.49 | $-0.28 | 0.00 |
| 2021-12-31 | 6.81 | $-0.31 | 0.00 |
| 2021-09-30 | 6.09 | $-0.35 | 0.00 |
| 2021-06-30 | 5.91 | $-0.36 | 0.00 |
| 2021-03-31 | 6.01 | $-0.36 | 0.00 |
| 2020-12-31 | 6.92 | $-0.36 | 0.00 |
| 2020-09-30 | 6.26 | $-0.39 | 0.00 |
| 2020-06-30 | 6.60 | $-0.44 | 0.00 |
| 2020-03-31 | 4.65 | $-0.48 | 0.00 |
| 2019-12-31 | 4.22 | $-0.52 | 0.00 |
| 2019-09-30 | 5.16 | $-0.52 | 0.00 |
| 2019-06-30 | 5.62 | $-0.50 | 0.00 |
| 2019-03-31 | 6.23 | $-0.47 | 0.00 |
| 2018-12-31 | 5.07 | $-0.44 | 0.00 |
| 2018-09-30 | 7.21 | $-0.42 | 0.00 |
| 2018-06-30 | 6.67 | $-0.43 | 0.00 |
| 2018-03-31 | 5.48 | $-0.49 | 0.00 |
| 2017-12-31 | 3.38 | $-0.56 | 0.00 |
| 2017-09-30 | 2.73 | $-0.59 | 0.00 |
| 2017-06-30 | 2.51 | $-0.61 | 0.00 |
| 2017-03-31 | 4.45 | $-0.63 | 0.00 |
| 2016-12-31 | 4.35 | $-0.62 | 0.00 |
| 2016-09-30 | 6.21 | $-0.64 | 0.00 |
| 2016-06-30 | 6.24 | $-0.67 | 0.00 |
| 2016-03-31 | 5.93 | $-0.66 | 0.00 |
| 2015-12-31 | 6.32 | $-0.66 | 0.00 |
| 2015-09-30 | 4.54 | $-0.76 | 0.00 |
| 2015-06-30 | 5.19 | $-0.74 | 0.00 |
| 2015-03-31 | 4.17 | $-0.73 | 0.00 |
| 2014-12-31 | 6.24 | $-0.68 | 0.00 |
| 2014-09-30 | 4.01 | $-0.53 | 0.00 |
| 2014-06-30 | 4.15 | $-0.67 | 0.00 |
| 2014-03-31 | 4.80 | $-0.60 | 0.00 |
| 2013-12-31 | 6.45 | $-0.65 | 0.00 |
| 2013-09-30 | 6.72 | $-0.62 | 0.00 |
| 2013-06-30 | 4.42 | $-0.41 | 0.00 |
| 2013-03-31 | 4.42 | $-0.42 | 0.00 |
| 2012-12-31 | 3.16 | $-0.42 | 0.00 |
| 2012-09-30 | 3.40 | $-0.51 | 0.00 |
| 2012-06-30 | 3.32 | $-0.38 | 0.00 |
| 2012-03-31 | 4.02 | $-0.41 | 0.00 |
| 2011-12-31 | 2.80 | $-0.35 | 0.00 |
| 2011-09-30 | 2.12 | $-0.25 | 0.00 |
| 2011-06-30 | 3.00 | $-0.40 | 0.00 |
| 2011-03-31 | 2.91 | $-0.41 | 0.00 |
| 2010-12-31 | 2.46 | $-0.43 | 0.00 |
| 2010-09-30 | 3.84 | $-0.50 | 0.00 |
| 2010-06-30 | 3.16 | $-0.56 | 0.00 |
| 2010-03-31 | 2.79 | $-0.61 | 0.00 |
| 2009-12-31 | 1.99 | $-0.71 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.230B | $0.180B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.741B | 26.94 |
| Boston Scientific (BSX) | United States | $155.895B | 37.18 |
| Stryker (SYK) | United States | $147.123B | 29.95 |
| EssilorLuxottica (ESLOY) | France | $145.891B | 0.00 |
| Medtronic (MDT) | Ireland | $116.772B | 16.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.160B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.031B | 25.15 |
| ResMed (RMD) | United States | $42.217B | 30.19 |
| GE HealthCare Technologies (GEHC) | United States | $33.398B | 15.70 |
| Agilent Technologies (A) | United States | $33.278B | 21.69 |
| Terumo (TRUMY) | Japan | $27.302B | 32.35 |
| Koninklijke Philips (PHG) | Netherlands | $26.423B | 17.48 |
| Insulet (PODD) | United States | $23.078B | 77.32 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.685B | 13.17 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.192B | 0.00 |
| Baxter (BAX) | United States | $12.250B | 9.46 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.714B | 28.33 |
| Lantheus Holdings (LNTH) | United States | $4.023B | 10.88 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.400B | 23.79 |
| Perrigo (PRGO) | Ireland | $3.224B | 8.05 |
| Prestige Consumer Healthcare (PBH) | United States | $3.221B | 14.29 |
| ICU Medical (ICUI) | United States | $3.005B | 20.46 |
| Haemonetics (HAE) | United States | $2.601B | 11.61 |
| LeMaitre Vascular (LMAT) | United States | $2.183B | 46.82 |
| Acuren (TIC) | United States | $2.054B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.918B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.804B | 77.48 |
| AtriCure (ATRC) | United States | $1.776B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.742B | 10.97 |
| Phibro Animal Health (PAHC) | United States | $1.279B | 16.35 |
| AdaptHealth (AHCO) | United States | $1.261B | 17.92 |
| Tilray Brands (TLRY) | Canada | $1.222B | 0.00 |
| Neogen (NEOG) | United States | $1.216B | 19.31 |
| BioLife Solutions (BLFS) | United States | $1.201B | 2508.00 |
| Valneva SE (VALN) | France | $0.952B | 0.00 |
| InMode (INMD) | Israel | $0.898B | 8.31 |
| Kestra Medical Technologies (KMTS) | United States | $0.876B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.622B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.609B | 0.00 |
| SNDL (SNDL) | Canada | $0.589B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.587B | 0.00 |
| ZimVie (ZIMV) | United States | $0.534B | 20.58 |
| Surmodics (SRDX) | United States | $0.516B | 0.00 |
| Evolus (EOLS) | United States | $0.480B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.471B | 16.20 |
| CeriBell (CBLL) | United States | $0.428B | 0.00 |
| Owens & Minor (OMI) | United States | $0.392B | 3.48 |
| Sanuwave Health (SNWV) | United States | $0.354B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.321B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Omeros (OMER) | United States | $0.305B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.303B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.297B | 0.00 |
| Brainsway (BWAY) | Israel | $0.283B | 57.65 |
| Viemed Healthcare (VMD) | United States | $0.273B | 20.74 |
| High Tide (HITI) | Canada | $0.273B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.272B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.270B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.231B | 0.00 |
| Quanterix (QTRX) | United States | $0.225B | 0.00 |
| Exagen (XGN) | United States | $0.220B | 0.00 |
| Organigram Global (OGI) | Canada | $0.210B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.209B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.184B | 15.37 |
| FitLife Brands (FTLF) | United States | $0.155B | 19.10 |
| Biote (BTMD) | United States | $0.149B | 4.95 |
| Jushi Holdings (JUSHF) | United States | $0.131B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.17 |
| Quipt Home Medical (QIPT) | United States | $0.092B | 0.00 |
| MacroGenics (MGNX) | United States | $0.091B | 0.00 |
| Jin Medical (ZJYL) | China | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.084B | 0.00 |
| Apyx Medical (APYX) | United States | $0.078B | 0.00 |
| Safety Shot (SHOT) | United States | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.054B | 31.47 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| Veru (VERU) | United States | $0.052B | 0.00 |
| Zynex (ZYXI) | United States | $0.046B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 33.50 |
| Rockwell Medical (RMTI) | United States | $0.040B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 14.82 |
| Trinity Biotech (TRIB) | Ireland | $0.028B | 0.00 |
| Senestech (SNES) | United States | $0.022B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |